Last €35.50 EUR
Change Today +0.10 / 0.28%
Volume 16.6K
GIMB On Other Exchanges
Symbol
Exchange
EN Brussels
Stuttgart
As of 11:35 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

gimv nv (GIMB) Snapshot

Open
€35.65
Previous Close
€35.40
Day High
€35.70
Day Low
€35.41
52 Week High
06/19/14 - €39.10
52 Week Low
10/16/14 - €34.16
Market Cap
902.6M
Average Volume 10 Days
22.9K
EPS TTM
€0.61
Shares Outstanding
25.4M
EX-Date
06/27/14
P/E TM
58.2x
Dividend
€2.45
Dividend Yield
6.90%
Current Stock Chart for GIMV NV (GIMB)

Related News

No related news articles were found.

gimv nv (GIMB) Related Businessweek News

No Related Businessweek News Found

gimv nv (GIMB) Details

GIMV NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, replacement capital, bridge financing, recapitalization, and PIPES. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer 2020; health and care; smart industries; and sustainable cities. It mainly focuses on European market and midcap companies in Flanders and Brussels, and also invests in Kazakhstan, Germany, France, Italy, Luxembourg, Netherlands, United Kingdom, Russia, Czech Republic, and Slovakia. Within consumer 2020, it focuses on consumer goods, food and beverage, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. It invests in small and medium sized businesses primarily with headquarters in the Benelux, France, and Germany with an enterprise value of up to €125 million ($172.94 million). Within health and care sector it focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services based companies with headquarters in Benelux, France and Germany (DACH). It typically makes investments between €3 million ($4.15 million) to €10 million ($13.84 million) in the biopharma and medtech and up to €10 million ($13.84 million) to €30 million ($41.50 million) in the health & care services. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource e?cient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software & services harnessing the ?exibility of the cloud, smart data management and advanced computation power, and components and systems for e?cient use of energy, in terms of production, storage, management, use and transport based small to medium companies with headquarters in the Benelux, France and Germany (DACH) targeting an international customer base. It invests in companies with an enterprise value of up to €125 million ($172.94 million). It also makes flexible equity investment (equity, semi-equity, minority or majority) but always with a meaningful impact on the company and an exit trigger. Within smart industries, it focuses on Products, services and infrastructure for building sustainable urban societies: Utilities and consumer goods related to energy and other (raw) materials, Waste treatment, recycling and recovery, Construction & Infrastructure, Transport & Logistics Services, and biomass, green (= sustainable) chemistry, water, offshore & maritime solutions and energy e?cient infrastructure. It invests through (mezzanine, equity, minority or majority) but will always strive to have a meaningful impact on the company strategy and need an exit trigger. It also invests in semiconductors, chemicals, agriculture, clean technology, electronics, water processing and purification technologies. For fund of fund investments, it seeks to invest in Europe. It typically invests between $3.73 million and $425.439 million in companies with an enterprise value between $106.04 million and $1060.44 million and sales value ranging from $6.67 million to $567.252 million. It may take a majority or a minority stake in its portfolio companies. Its investment horizon is between four and seven years. It also seeks a board seat in its portfolio companies. It invests with capital from its own balance sheet and through various funds under management. GIMV NV was founded on February 25, 1980 and is based in Antwerp, Belgium with additional offices in Paris, France; Netherlands, The Netherlands; Frankfurt am Main, Germany; London, United Kingdom; Prague, Czech Republic; Warsaw, Poland; and Munich, Germany.

99 Employees
Last Reported Date: 05/20/14
Founded in 1980

gimv nv (GIMB) Top Compensated Officers

Chief Executive Officer, Managing Director, D...
Total Annual Compensation: €674.2K
Compensation as of Fiscal Year 2014.

gimv nv (GIMB) Key Developments

GIMV NV Approves Dividend Payable August 1, 2014

Gimv held its General Shareholders' Meeting on June 25, 2014. The AGM approved the gross dividend of EUR 2.45 per share for the fiscal 2014. Ex-date dividend is June 27, 2014. Record date July 1, 2014. Payment date of the dividend is August 1, 2014.

GIMV NV Reports Consolidated Earnings Results for the Year Ended March 31, 2014

GIMV NV reported consolidated earnings results for the year ended March 31, 2014. For the period, the company reported operating income of EUR 159,056,000 compared to EUR 200,788,000 for the same period a year ago. Turnover was EUR 2,862,000 compared to EUR 8,694,000 last year. Operating result was EUR 12,494,000 compared to EUR 27,440,000 last year. Result before tax was EUR 16,934,000 compared to EUR 32,359,000 last year. Net profit for the period was EUR 15,254,000 compared to EUR 30,562,000 last year. Net profit attributable to equity holders of the parent was EUR 14,998,000 or EUR 0.61 per basic and diluted share compared to EUR 32,746,000 or EUR 1.37 per basic and diluted share last year. Net cash flows used in operating activities was EUR 14,953,000 compared to EUR 46,135,000 last year. Purchase of property, plant and equipment was EUR 939,000 compared to EUR 211,000 last year.

GIMV NV Presents at EuroMedtech 2014, May-06-2014

GIMV NV Presents at EuroMedtech 2014, May-06-2014 . Venue: Marriott Linz Hotel, Europaplatz 2, A-4020, Linz, Austria.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GIMB:BB €35.50 EUR +0.10

GIMB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GIMB.
View Industry Companies
 

Industry Analysis

GIMB

Industry Average

Valuation GIMB Industry Range
Price/Earnings 53.3x
Price/Sales 5.1x
Price/Book 0.8x
Price/Cash Flow 52.0x
TEV/Sales 5.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GIMV NV, please visit www.gimv.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.